-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atrial fibrillation is a risk factor for dementia, and the use of oral anticoagulants is related to the reduced risk of dementia in patients with atrial fibrillation
.
Recently, the heart blood vessels published a research article on the disease areas authoritative journal Stroke, researchers to investigate patients receiving (DOAC) direct oral anticoagulant treatment compared with patients receiving warfarin therapy, the risk of dementia Is it different
.
The researchers used the Korean National Claims Database from January 2014 to December 2017 to identify non-valvular atrial fibrillation patients over 40 years of age who did not use oral anticoagulants
.
For comparison, the warfarin group and the DOAC group were balanced using a treatment-weighted inverse probability method
The study included 72,846 patients, 25,948 received warfarin, 46,898 received DOAC (17,193 rivaroxaban, 9882 dabigatran, 11992 apixaban , 7831 edoxaban )
.
During an average follow-up of 1.
Apixaban stroke In this large Asian AF population, overall, DOAC has a risk of dementia similar to that of warfarin
Original source:
So-Ryoung Lee.
et al.
Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation .
stroke.
2021.